

ASSIGNMENT

WHEREAS WE, Kerstin Allen; Marcus Yountz; Stephan Ortiz; and Fanny O'Brien; for good and valuable consideration, the receipt of which is hereby acknowledged, have invented

COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMYELITIS OPTICA SPECTRUM DISORDER,

described in an application for patent,

☐ the specification of which is about to be filed in the United States Patent Office (for utility 37 CFR 1.53(b) and design filings);

☐ is about to be filed in the United States Patent and Trademark Office as a Provisional Application;

☐ the specification of which is United States Application No. [], filed []; and

☒ the specification of which is a Patent Cooperation Treaty Application, International Application No. PCT/US2020/063781, filed December 08, 2020 which claims the benefit of the following application:

United States Provisional Application No. 62/945,644, filed December 09, 2019;

☐ which was patented as United States Patent No. [];

AND,

WHEREAS Alexion Pharmaceuticals, Inc. (hereinafter "ASSIGNEE"), a corporation organized and existing under the laws of Delaware, and having a usual place of business at 121 Seaport Boulevard, Boston, Massachusetts 02210, desires to acquire an interest therein in accordance with agreements duly entered into with us;

NOW, THEREFORE we do hereby sell, assign and transfer unto ASSIGNEE, its successors, assigns and legal representatives, the entire right, title and interest in and throughout the United States of America, its territories and all foreign countries, in and to said invention as described in said application, together with the entire right, title and interest in and to said application and such Letters Patent as may or shall issue on said invention, or any parts thereof, or any divisional, continuing, reissue or other application(s) based in whole or in part thereon; said invention, application and Letters Patent to be held and enjoyed by said ASSIGNEE for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said Letters Patent may be granted as fully and entirely as the same would have been held by us had this assignment and sale not been made; we hereby further convey all rights, including rights of priority, arising under or pursuant to any and all international agreements, treaties or laws relating to the protection of industrial property. We hereby acknowledge that this assignment, being of the entire right, title and interest in and to said invention, carries with it the right in ASSIGNEE to apply for and obtain from competent authorities in all countries of the world any and all Letters Patent by attorneys and agents of ASSIGNEE's selection and the right to procure the grant of all such Letters Patent to ASSIGNEE for its own name as assignee of the entire right, title and interest therein.

We hereby further agree for ourselves and our executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts that may be deemed necessary to secure fully the aforesaid invention to said ASSIGNEE, its successors, assigns and legal representatives, but at its or their expense and charges, including the execution of applications for patents in foreign countries, and the execution of any future applications including substitution, reissue, divisional or continuation applications, and preliminary or other statements and the giving of testimony in any interference or other proceeding in which said invention or any application or patent directed thereto may be involved;

We do hereby authorize and request the Commissioner of Patents and Trademarks of the United States, or foreign examining authority, to issue such Letters Patent as shall be granted upon said application or applications based thereon to ASSIGNEE, its successors and assigns.

23 June 2021
Date


Kerstin R Allen
Kerstin Allen

Witness:

6/23/2021
Date


MARC H. ALLEN
Witness Name:
MARC H. ALLEN

7/1/21
Date


Marcus Yountz

Witness:

07/01/21
Date



Witness Name:
Suzanne Galvin

23 JUN 2021
Date


Stephan Ortiz

Witness:

June 23 2021
Date


Witness Name:

June 23, 2021
Date

Fanny O'Brien
Fanny O'Brien


Witness:

June 23, 2021
Date

Edward J. O'Brien
Witness Name:

ASSIGNEE:

I hereby acknowledge that rights in the above-identified application have transferred from the assignor(s) by virtue of their above execution of this Assignment and are hereby conveyed to Alexion Pharmaceuticals, Inc., the Assignee, of which I am an authorized signatory.



Todd Spalding

S.V.P., Head of Intellectual Property

Signatory Title (print)

Alexion Pharmaceuticals, Inc.

Date: July 12, 2021